Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/1703522.pdf
Reference19 articles.
1. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents New Engl J Med 1984 310: 1353 1356
2. Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma Lancet 1989 2: 882 885
3. Kantarjian H, Dreicer R, Barlogie B et al. High dose cytosine arabinoside in multiple myeloma Eur J Clin Oncol 1984 20: 227 231
4. Ganjoo RK, Williams A, Malpas J . Vincristine and oral etoposide in refractory multiple myeloma Cancer Chemother Pharmacol 1995 35: 343 344
5. Barlogie B, Velasquez WS, Alexanian R et al. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma J Clin Oncol 1989 7: 1514 1517
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Thalidomide: Chemistry, Therapeutic Potential and Oxidative Stress Induced Teratogenicity;Current Topics in Medicinal Chemistry;2012-07-01
2. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield;Leukemia;2007-03-22
3. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis;Leukemia & Lymphoma;2006-01
4. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma;European Journal of Haematology;2005-01
5. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma;British Journal of Cancer;2004-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3